Interleukin-2 (IL-2) production in vitro is depressed in systemic lupus erythematosus (SLE) patients. It is not known whether this abnormality is caused by a defect in the producer lymphocytes or by excessive suppression. We report that removal of OKT8 (Leu 2a)+ cells increased the IL-2 production by in vitro-stimulated lymphocytes to normal or above normal levels in 19 of 21 SLE patients. This increase was more apparent in those patients with clinically inactive disease and/or receiving <7.5 mg of prednisone. Removal of OKT8+ cells from normals did not significantly increase IL-2 activity. SLE, but not normal, OKT8+ cells decreased IL-2 production when added back to autologous OKT8-depleted cells. In some experiments, OKT8+ cells from normal donors also suppressed IL-2 production in SLE. This result suggests that the defect in IL-2 production is complex and may involve multiple cell interactions. Three lines of evidence suggest that the SLE OKT8+ cells actively inhibit the production of IL-2 rather than passively absorb this lymphokine: (a) only 3.2% of SLE lymphocytes expressed IL-2 receptors as detected with anti-Tac; (b) freshly prepared SLE lymphocytes did not absorb IL-2; and (c) cellfree supernatants from SLE OKT8+ cells inhibited IL-2 production, but not IL-2 activity. Double-labeling studies by flow cytometry revealed that 19.3% of SLE OKT8+ cells were also Ia-positive, and -33% co-expressed the natural killer cell marker, HNK-1 (Leu 7). Removal of Leu 7+ cells also significantly elevated IL-2 production in SLE. These studies suggest that one or more circulating mononuclear cell subsets in SLE patients can suppress IL-2 production and that one subset may possibly belong to a non-T, non-B "third mononuclear population."
Introduction
Systemic lupus erythematosus (SLE)V is a disorder characterized by B lymphocyte hyperactivity resulting in increased immu-noglobulin and autoantibody formation. The initial factors responsible for the increased antibody formation are poorly understood. Decreased numbers of T suppressor cells (1) and suppressor function (2, 3) have been proposed as the causes for this defect. However, many SLE patients have relatively increased circulating OKT8+ cells (4, 5) , and some workers have found suppressor cell activity intact (6) .
Interleukin-2 (IL-2) is required for clonal expansion of both helper and suppressor cells (7) . Recently, we and others (8, 9) have reported decreased in vitro production of IL-2 by blood lymphocytes in SLE. This decrease could be explained by a defective producer cell or by the presence of an inhibitory cell. In this article, we report that the principal mechanism for decreased IL-2 production in SLE is active inhibition. Removal of an OKT8+ subset elevated IL-2 levels to normal or abovenormal levels in 19 of 21 patients with both active and inactive disease. Removal of natural killer cell marker (HNK-1 )+ cells also corrected IL-2 production. Evidence will be presented to show that the OKT8+ cells actively suppressed IL-2 production rather than passively absorbed newly released lymphokine.
Methods
21 patients who fulfilled the 1982 revised criteria of the American Rheumatism Association for SLE (10) were selected from the inpatient and outpatient services of our section. The clinical and serologic features of the patients are shown in Table I . All were women whose ages ranged from 19 to 50 yr with a mean of 29.8±1.6 yr. 14 patients were Hispanic-Americans, 3 were Caucasians, and 4 were Blacks. The duration of the disease ranged from 0.4 to 18 yr with a mean of 5.4±0.9 yr.
The patients were divided into two groups: group 1-5 patients with stable or inactive disease; group 11-16 patients with manifestations of both clinical and serologic activity. Clinically active disease was defined as the involvement of three or more organs at the time of the study (see footnotes to Table I ).
Active serology was defined as the presence of two or more of the following: low serum complement (C'H50) (normal values = 480-960 U), a positive Crithidia luciliae test for anti-DNA antibodies (normal value = <1:10), and elevated levels of serum cryoglobulins (normal value < 3 mg/dl). Duration of disease and dose of prednisone are also mentioned in this table.
After the blood specimens were obtained, the prednisone dose was increased in nine patients of group II. Paired controls were normal donors matched for sex, age, and ethnic background.
Monoclonal antibodies. The following monoclonal antibodies were used in these studies: OKT8 and OKT4 purchased from Ortho Pharmaceutical, Raritan NJ; Leu 2, purchased from Becton, Dickinson & Co., Mountainview, CA; HNK-1 (Leu 7) generously provided by Dead cells, erythrocytes, platelets, and monocytes were excluded from analysis by gating on the lymphocyte cluster using forward light scatter on the FACS IV or axial extinction and 90°light scatter on the Ortho 50 H. The total percent positive refers to the percent of 5,000 lymphocytes with fluorescence >99% of the background control. The fraction of the subpopulation that double-labeled was calculated as follows: % double-labeled = (% of lymphocytes bearing two colors)/ (% of lymphocytes bearing one color) X 100.
Cell separation techniques. Venous peripheral blood cells from SLE patients and paired healthy controls were separated on a FicollHypaque density gradient and mononuclear cells (PBM) were washed three times and separated by cell sorting or by panning. Both methods gave similar results and were used interchangeably.
For cell sorting, PBM from either normal donors or lupus patients were labeled with monoclonal antibodies for 30 min on ice. The antibodies used were OKT8, OKT4, and HNK-I (Leu 7). After washing twice with cold RPMI-I% fetal calf serum, the cells were resuspended in FITC-conjugated goat-antimouse IgG (Cappel Laboratories, Inc.) and kept for 30 min on ice, washed once, and sorted.
Cell sorting was performed on a fluorescence-activated cell sorter (FACS IV or Cytofluorograph 50 H). In addition, the percent of positive lymphocytes with more intense fluorescence than 99% of the background control was used to calculate the OKT4 to OKT8 ratio for both normals and patients. For the background control, a nonspecific mouse IgG ascites fluid (Bethesda Research Laboratories) was substituted for the first antibody. The purity of sorted cells was >97%.
The second method we used to isolate human mononuclear cell populations was by panning as described by Engleman et al. (1 1 In vitro IL-2 production and assay. In that we had previously found that stimulation of cells with both phytohemagglutinin (PHA) and Daudi cells, a lymphoblastoid cell line, resulted in at least 10-fold higher IL-2 values at 24 h of culture than with PHA alone (8), this procedure was used mostly in this study. Briefly, 2 X 106 lymphocytes per milliliter were co-cultured with equal amounts of Daudi cells, and 0.1% bacto phytohemagglutinin M (PHA-M), in RPMI 1640 supplemented with 5% fetal calf serum, 2.0 mM L-glutamine and 10 ,g/ml gentamicin. After 24 h, supernatants were collected and checked for IL-2 activity in a proliferation assay that used CTLL cells, a murine IL-2-dependent cell line. IL activity (expressed as units per milliliter) was calculated by probit analysis using as reference a standard rat IL-2 preparation.
In some experiments, positively selected OKT8+ cells were harvested from panning trays, added to equal amounts of OKT8-depleted PBM, and stimulated to produce IL-2 by a 24-h incubation with 1% PHA-M.
Production of a soluble IL-2 inhibitory factor. Positively selected cells were adjusted to 2 X 106/ml in culture medium and incubated for 18 h at 37°C in 5% CO2. After this, the cells were spun, and supernatants were harvested and stored frozen at -20°C.
Results
Effect ofdepletion of OKT8+ cells on IL-2 production in vitro.
We measured production of IL-2 by PBM of SLE patients and paired controls after stimulation with PHA and Daudi cells for 24 h (Fig. 1) . In agreement with our previous results, levels of IL-2 in SLE were markedly decreased (mean±SEM: 12 depleted SLE Figure 1 . In vitro correction of IL-2 production (U/ml) by PBM from SLE patients after removal of OKT8+ cells. 2 X 106/ml PBM were co-cultured with 2 X 106/ml Daudi cells and 1% PHA for 24 h. OKT8+ cells were removed by cell sorting or by panning. The patients with IL-2 values between 128 and 207 U/ml after OKT8+ cell depletion were V.J., M.E., R.R., and C.S. (see Table I ). U/ml vs. 33.8±5.6 U/ml in controls). Depletion of OKT8+ cells in SLE either by cell sorting or by panning corrected this defect. IL-2 levels in SLE were increased two-to fivefold in 19 of the 21 patients studied and values increased to the normal or above the normal range. Depletion of OKT8+ cells in normal controls did not significantly increase IL-2 production (Fig. 1) , although this procedure did result in a twofold elevation in five subjects. Depletion of OKT4+ cells abolished almost completely IL-2 production in all subjects studied. This was expected in that OKT4+ cells are the principal producers of IL-2 in this system (12) .
The SLE patients studied were grouped by disease activity (Table 1) . In both groups IL-2 values were depressed to -33% of normal. After OKT8 (Leu 2)+ cell depletion, the mean IL-2 value in both groups was increased, but the IL-2 production in the inactive patients was significantly higher than in the active group production of allogeneic normal lymphocytes stimulated by PHA. Table IV shows that at a 1:15 dilution, supernatants of SLE OKT8+ cells inhibited IL-2 production by >50%. These supernatants did not block IL-2 activity inasmuch as they had no inhibitory effect on the response of the CTLL cell line to purified human IL-2 (Table IV) . These results were repeated in six additional experiments where the PBM were derived each time from a different normal donor. Depletion of HNK-J (Leu 7)+ cells. Besides reacting with T cytotoxic/suppressor cells, the OKT8 monoclonal antibody reacts with -30% of "large granular lymphocytes" isolated by Percoll gradient centrifugation (14), or with OKM-I+ lymphocyte-sized cells isolated by flow cytometry (15) . Both methods of separation enrich for cells whose functional activities include cytotoxic and immunoregulatory effects (16) . The majority of cells in the OKMI+ fraction react with Leu 7 (HNK-1), a monoclonal antibody which has been associated with natural killer cells (17) . Therefore, we considered the possibility that OKM1+, Leu 7+ cells also might be capable of suppressing IL-2 production in SLE. Lymphocytes from SLE patients and normal controls were depleted of Leu 7+ or Leu 2+ cells by panning and then stimulated to produce IL-2. Table V illustrates results of two such experiments. As before, depletion of Leu 2a+ cells elevated IL-2 production in SLE. We observed that removal of Leu 7+ cells, in SLE also markedly elevated IL-2 production. In these studies depletion of both Leu 2a+ and Leu 7+ cells increased IL-2 production in the two normal subjects. Similar results were observed in four experiments using a total of four normals and eight SLE donors. Controls were PBM panned over petri dishes coated with goat anti-mouse antibody without prior incubation with monoclonal antibody. This procedure did not enhance IL-2 production.
Possible increased sensitivity ofSLE IL-2 producer cells to suppressive signals. To characterize further the mechanisms responsible for the IL-2 defect in SLE, we performed allogeneic add-back experiments whereby OKT8 (Leu 2a)+ cells from one SLE donor were added to OKT8-depleted cells from another SLE patient or a normal. We also investigated the effects of OKT8+ cells from normals added to SLE OKT8-depleted cells. The results of one of four experiments are shown in Table VI . These studies revealed that although there was autologous suppression as described before, OKT8+ cells from two SLE donors did not suppress IL-2 production by normal OKT8-depleted cells, and in only one case did SLE cells from one donor inhibit the other. There are other reports of spontaneously activated blood mononuclear cells in SLE. We have described spontaneously proliferating cells (25) and others have reported evidence of activated T cells in this disorder (26) . Because removal of suppressor cells from the cell suspensions of some normal donors also elevated IL-2 production, it is likely that the findings in SLE reflect augmentation of a physiologic regulatory mechanism instead of an aberrant phenomenon. Although the monoclonal antibody OKT8 (Leu 2) labels T suppressor cells, the cell type inhibiting IL-2 secretion requires further characterization. The additional finding that removal of Leu 7 (HNK-2)+ cells enhances IL-2 production in SLE and in normals also, suggests that cells from a non-T, non-B, third mononuclear population (16) might be involved in IL-2 regulation. In addition to their well-known cytotoxic properties, these cells regulate hematopoiesis in mice (27) , and suppress granulocyte (28) and antibody production (29) in humans. Inasmuch as 33% of OKT8 (Leu 2a)+ cells bear the HNK-1 marker, it is possible that this is one of the subsets responsible for the suppression we have described.
Unregulated immunoglobulin production in SLE has been considered to be a result of inadequate suppression. There is abundant evidence of impaired T suppressor cell activity in SLE (2, 3, 30) although there are some workers who reported that suppressor cell activity is intact (6, 31) . Our observation of excessive suppressor cell activity may, at first glance, appear paradoxical, but not if one can ultimately distinguish cells that inhibit production of immunoglobulin from cells that suppress IL-2 production.
Excessive suppression of IL-2 production may not be a feature unique to SLE. A similar defect in IL-2 production in vitro has been reported in recipients of bone marrow transplants (32) and decreased mitogenic responsiveness in lepromatous leprosy may also be caused by suppression of IL-2 production (33) .
The mechanism responsible for activation of suppressor cells in SLE is a matter of speculation. The finding of above normal IL-2 values after removal of OKT8+ cells in some patients with inactive disease may yield a clue. Most of the abnormalities in cell mediated immunity in SLE fluctuate with disease activity and probably, reflect secondary manifestations of the disease rather than significant pathogenetic events. If studies on larger numbers of inactive patients and family members will reveal the abnormal IL-2 production we have described here, this defect may be added to the list of hormonal and genetic factors that may be important in the pathogenesis of SLE.
